Combinations ; - see below
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Alendron | Troikaa Pharmaceuticals | Europa Healthcare Ltd. | 70mg | 12 | Tablet | per tablet | KES 600 |
| Bifosa | Troikaa Pharmaceuticals | Europa Healthcare Ltd. | 70mg | 4 | Tablet | per tablet | KES 520 |
| Bongard | Laborate | Harley's Limited | 70mg | 4 | Tablet | per tablet | KES 513.00 |
| Fosavance | Merck Sharp & Dohme | Phillips Pharmaceuticals Ltd. | 70mg | 4 | Tablet | per tablet | KES 5,500 |
| Menofos | Cipla Ltd. | Lords Healthcare Ltd. | 70mg | 10 | Tablet | per tablet | KES 1,644.50 |
| Reventa | Getz Pharmaceuticals | Surgipharm Ltd | 70mg | 4 | Tablet | per tablet | KES 794.00 |
| Bifosa 70 | Troikaa Pharmaceuticals | Harley's Limited | 70mg | 4 | Tablet | per tablet | KES 600.00 |
| Osteofos | Cipla Ltd. | Surgipharm Ltd | 70mg | 10 | Tablet | per tablet | KES 1,950.00 |
| Alendronate More info | |
|---|---|
| Mode Of Action | Aminobisphosphonates act as specific inhibitors of osteoclast-mediated bone resorption. They bind to the hydroxyapatite in bones. |
| Drug Indication | Osteoporosis in postmenopausal women, prevention of osteoporosis in postmenopausal women and Paget's disease of bones |
| Precautions | Renal insufficiency; hypocalcemia and other disturbances of mineral metabolism need to be corrected before initiating therapy with this drug; tablets are taken with plain water the first thing in the morning (at least 30 minutes before the first food, beverage, or medication of the day). |
| Contra-Indications | Hypocalcemia; abnormalities of the esophagus which delay emptying such as stricture or achalasia; for those who cannot stand or sit upright for at least 30 minutes; hypersensitivity to any component of the product. |
| Side Effects | Side effects are generally rare and mild; GI disturbances; headache; taste perversion; musculo-skeletal pain; hypersensitivity reactions. |
| Dosage | Osteoporosis in postmenopausal women: 10mg OD. Prevention of osteoporosis in postmenopausal women: 5mg OD. Paget's disease of bone: 40mg OD x 6/12. |
| Pregnancy Category | Category B3 |
| Pregnancy Category Description | Drugs which have been taken by only a small number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. Studies in animals show evidence of an increased occurrence of foetal damage, the significance of which is uncertain in human |
| Drug Category | DRUGS AFFECTING NUTRITION AND METABOLISM |
| Drug Sub-Category | Bisphosphonates |